PALM SPRINGS, Calif., Sept. 6, 2024 /PRNewswire/ — Leading physicians and researchers will present results from 21 clinical trials from Sunday, November 3, to Tuesday, November 5, at the annual VIVA and The VEINS conferences at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is a…
Tag: VIVA
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Nov. 1, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the last of four Late-Breaking Clinical Trial sessions at the VIVA23…
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Nov. 1, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four Late-Breaking Clinical Trial sessions at the VIVA23…
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Oct. 31, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four Late-Breaking Clinical Trial sessions at the…
Late-Breaking Clinical Trial Results Announced at The VEINS 2023
LAS VEGAS, Oct. 30, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the Late-Breaking Clinical Trials session at The VEINS conference,…
Boston Scientific Announces Positive Data for the Ranger™ Drug-Coated Balloon and the Eluvia™ Drug-Eluting Vascular Stent at VIVA19
Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive data for two devices […]
PQ Bypass to Unveil New Data From DETOUR I at VIVA 17
SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass today announced that data from a subset analysis of the DETOUR I clinical trial will be presented during a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), taking place September 11-14 in Las Vegas. […]